Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration

American Journal of Ophthalmology

Volumn 158, Issue 4, 2014, Pages 738-744.e1

  Wang, Xiying ^a,b   Sawada, Tomoko ^a   Sawada, Osamu ^a   Saishin, Yoshitsugu ^a   Liu, Ping ^b   Ohji, Masahito ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERVENTION STUDY; LIMIT OF DETECTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXUDATIVE MACULAR DEGENERATION; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; VERY ELDERLY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84908553704     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.06.009     Document Type: Article

References (39)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291(15):1900-1901.
2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004;122(4):477-485.
3. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82(11):844-851.
4. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neo vascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92(23):10457-10461.
5. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Trans differentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neo vascular membranes. Invest Ophthalmol Vis Sci 1996; 37(5):855-868.
6. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37(9):1929-1934.
7. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81(2): 154-162.
8. Jonas JB, Neumaier M. Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema. Ophthalmic Res 2007;39(3):139-142.
9. Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol 2009;148(5):718-724.
10. Funk M, Karl D, Georgopoulos M, et al. Neo vascular age related macular degeneration: Intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 2009;116(12):2393-2399.
11. Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M. Aqueous vascular endothelial growth factor after intra vitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. Retina 2010; 30(7):1034-1038.
12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431.
13. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432-1444.
14. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neo vascular age related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65.
15. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119(12):2537-2548.
16. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99(17):11393-11398.
17. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246(4935):1306-1309.
18. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-676.
19. Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290(2):H547-H559.
20. Liu MH, Jin H, Floten HS, Ren Z, Yim AP, He GW. Vascular endothelial growth factor-mediated, endothelium-dependent relaxation in human internal mammary artery. Ann Thorac Surg 2002;73(3):819-824.
21. Wang X, Sawada T, Kakinoki M, et al. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2014;252(7):1033-1039.
22. Machaliñska A, Paczkowska E, Pabin T, Safranow K, Karczewicz D, Machaliñski B. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis. J Ocul Pharmacol Ther 2011;27(5):471-475.
23. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol 2013;97(4):454-459.
24. Kakinoki M, Sawada O, Sawada T, Saishin Y, Kawamura H, Ohji M. Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys. Invest Ophthalmol Vis Sci 2012;53(9):5877-5880.
25. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo? Ann Oncol 1999; 10(8):965-971.
26. Gu X, Yu X, Dai H. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration. Curr Eye Res 2014;39(5): 518-521.
27. Haas P, Steindl K, Aggermann T, et al. Serum VEGF and CFH in exudative age-related macular degeneration. Curr Eye Res 2011;36(2):143-148.
28. Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res 2012;37(12):1171-1174.
29. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci 2010;51(3):1606-1608.
30. Brambell FW, Hemmings WA, Morris IGA. A theoretical model of gamma-globulin catabolism. Nature 1964;203: 1352-1354.
31. Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002;25(2):97-113.
32. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114(5):855-859.
33. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF Trap-Eye) in human eyes? Calculations with a mathematical model. Eye Reports 2011;1(1):e5.
34. US Food and Drug Administration. FDA labeling information: Eylea 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/125387lbl.pdf.Accessed November 2011.
35. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005; 46(2):726-733.
36. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27(5):536-544.
37. Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S. Pharmacokinetics of ranibizumab in patients with neo vascular age-related macular degeneration: A population approach. Invest Ophthalmol Vis Sci 2013;54(3):1616-1624.
38. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-1239.
39. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008; 300(19):2277-2285.